as 05-13-2024 4:00pm EST
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. The company has built a proprietary platform that includes a microbial library comprised of bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen the library of strains for drug-like molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically intractable strains.
Founded: | 2014 | Country: | United States |
Employees: | N/A | City: | BRANFORD |
Market Cap: | 7.5M | IPO Year: | 2023 |
Target Price: | N/A | AVG Volume (30 days): | 922.0K |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 0.80 | EPS Growth: | N/A |
52 Week Low/High: | $0.16 - $5.18 | Next Earning Date: | 05-09-2024 |
Revenue: | $572,700 | Revenue Growth: | 106.53% |
Revenue Growth (this year): | 123.03% | Revenue Growth (next year): | N/A |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Staskey Norm | AZTR | Chief Financial Officer | Mar 29 '24 | Buy | $0.21 | 47,600 | $10,034.08 | 51,100 | SEC Form 4 |
Staskey Norm | AZTR | Chief Financial Officer | Feb 13 '24 | Buy | $0.30 | 3,300 | $990.00 | 3,500 | SEC Form 4 |
AZTR Breaking Stock News: Dive into AZTR Ticker-Specific Updates for Smart Investing
Business Wire
4 days ago
Business Wire
4 days ago
Business Wire
21 days ago
Business Wire
25 days ago
Business Wire
2 months ago
Business Wire
3 months ago
Business Wire
3 months ago
GlobeNewswire
3 months ago